ncRNA-mediated upregulation of FAM83A is associated with poor prognosis and immune infiltration in pancreatic cancer

Frontiers in Endocrinology

Endocrinology

Kuiping Zhou¹  Gengyun Chang¹  Yuanshu Lian¹  Yunyang Wu¹  Gao Huang¹  Dingguo Wu¹  Jifeng Liang¹  Yuze Feng¹  Wenbo Zou¹  Hao Wang² 

[1] Department of General Surgery, No.924 Hospital of PLA Joint Logistic Support Force, Guilin, China;Neurology Department, No.924 Hospital of PLA Joint Logistic Support Force, Guilin, China;

关键词: FAM83A;    pancreatic cancer;    prognosis;    immune cell infiltration;    immunotherapy;   

DOI  :  10.3389/fendo.2023.1093042

 received in 2022-11-08, accepted in 2023-03-13,  发布年份 2023

来源: Frontiers

【 摘 要 】

IntroductionMalignant pancreatic cancer has poor long-term survival. Increasing evidence shows that FAM83A (family with sequence similarity 83 member A) plays a vital role in tumorigenesis and malignant progression in some human cancer types. The present study explored the potential mechanism of FAM83A in improving the prognosis of pancreatic cancer patients. MethodsTranscriptomic and clinical data from patients were obtained from The Cancer Genome Atlas while FAM83A expression was measured in tumorous pancreatic tissue compared with normal controls by quantitative real-time PCR and immunohistochemistry. ResultsFAM83A is a vital prognostic indicator and potential oncogene in pancreatic cancer via pan-cancer analysis. In silico analysis revealed that AL049555.1/hsa-miR-129-5p axis was the pivotal upstream ncRNA- mediated pathway of FAM83A in pancreatic cancer. Furthermore, FAM83A expression was related to immune cell infiltration through vital immune-related genes including programmed cell death 1 (PDCD1), and tumorigenesis through common mutation genes including KRAS protooncogene GTPase (KRAS), and SMAD family member 4 (SMAD4). In summary, ncRNA-mediated upregulation of FAM83A is associated with poor long-term survival and immune cell infiltration in pancreatic cancer. DiscussionFAM83A may be used as a novel survival-related and immune-related biomarker. This information suggests that FAM83A may be a novel therapeutic target for combined or individual treatment for patients with pancreatic cancer.

【 授权许可】

Unknown   
Copyright © 2023 Zou, Wang, Wu, Wu, Zhou, Lian, Chang, Feng, Liang and Huang